Impact of fish oils on the outcomes of a mouse model of acute Pseudomonas aeruginosa pulmonary infection

Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that causes pneumonia in immunocompromised humans and severe pulmonary damage in patients with cystic fibrosis. Imbalanced fatty acid incorporation in membranes, including increased arachidonic acid and decreased DHA concentrations, is known to play … Continued

KaloBios KB001-A fails Phase 2 study and discontinues development of KB001-A in cystic fibrosis

KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). While the data from this … Continued

Subcutaneous implant with etonogestrel for catamenial exacerbations in a patient with cystic fibrosis: a case report

Background Cystic Fibrosis (CF) is a genetic disease with equal prevalence across sexes. However, women present worse lung function with faster function decline, earlier onset of bacterial colonization, more frequent pulmonary exacerbations (PE), greater bronchial hyper-responsiveness, and higher mortality rates … Continued

NovaBiotics Receives Orphan Drug Status from the FDA for Lynovex for the Treatment of Cystic Fibrosis

NovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for Lynovex® (NM001), the Company’s first-in-class  therapeutic candidate for the treatment of Cystic Fibrosis (CF). CF is a … Continued

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

Background Consensus guidelines recommend early treatment to eradicate newly acquired Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) patients although there is no single preferred regimen. Aztreonam for inhalation solution (AZLI) significantly reduces sputum Pa density in CF patients with chronic Pa infection and has been … Continued

Agile Sciences has $1.5 million NIH grant to help develop its cystic fibrosis therapy derived from sea sponges

Raleigh biotechnology company Agile Sciences has landed a $1.5 million National Institutes of Health grant to help develop its cystic fibrosis therapy derived from sea sponges. Agile was spun out of North Carolina State University with the help of a $30,000 startup … Continued